JG
IBRX icon

Jefferies Group’s ImmunityBio IBRX Stock Holding History

Jefferies Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-41,881
Closed -$49K – 2464
2018
Q4 		$49K Buy
+41,881
New +$95.8K ﹤0.01% 2024
2015
Q4 		– Sell
-48,944
Closed -$561K – 2401
2015
Q3 		$561K Buy
+48,944
New +$1.07M ﹤0.01% 1458

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jefferies Group's IBRX Position: Q1 2019 in Review

Jefferies Group sold out of ImmunityBio (IBRX) in Q1 2019, closing a stake of 41,881 shares — an estimated $49K sold.

Jefferies Group first reported a position in IBRX in Q3 2015 and held it in 2 quarters. The position peaked at $561K in Q3 2015. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

  • Jefferies Group reported no remaining ImmunityBio position as of Q1 2019 after selling out during the quarter.
  • Jefferies Group sold 41,881 ImmunityBio shares in Q1 2019, an estimated $49K.
  • Jefferies Group first reported a position in ImmunityBio in Q3 2015 and held it in 2 quarters.
  • Jefferies Group's ImmunityBio position peaked at $561K in Q3 2015.
  • 58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on Jefferies Group's 13F filing for Q1 2019, filed 15 May 2019.